Posted by Michael Wonder on 07 Feb 2022
DoH publishes revised agenda for next month's PBAC meeting
7 February 2022 - The revised agenda notes three changes.
The Department of Health has revised the agenda for the March 2022 PBAC meeting.
The changes are as follows:
- Venetoclax (Venclexta) - submission for new presentation presumably withdrawn
- Nicotine replacement therapy – review of post-market review report presumably withdrawn
- Pembrolizumab (Keytruda) - new resubmission for patients with squamous cell carcinoma of the head and neck
